CDEK
← All drugs Report issue

cyclodextrin

Small moleculeexperimental

Cyclodextrins are a family of cyclic oligosaccharides, consisting of a macrocyclic ring of glucose subunits joined by α-1,4 glycosidic bonds. Cyclodextrins are produced from starch by enzymatic conversion. They are used in food, pharmaceutical, drug delivery, and chemical industries, as well as agriculture and environmental engineering. — Wikipedia

Clinical trial activity

14 trials · 22 clinical orgs · 0 marketing orgs

Phase 1
3
Phase 2
6
Phase 3
0
Phase 4
2

Earliest trial started Mar 1, 2010 (NCT01131299)

Timeline

2010s

  1. Jan 1, 2010

    Earliest Phase 2 Sponsor(trial)

  2. Jan 1, 2012

    Earliest Phase 1 Sponsor(trial)

Indications

Approved for

Studied for

Mechanism of action

Chemistry & pharmacology

Oral

No

Parenteral

No

Topical

No

Sources

Also known as

  • alpha cyclodextrin
  • alpha cyclodextrin
  • alpha-cyclodextrin
  • alpha-cyclodextrin
  • alpha-cyclodextrin
  • cyclodextrin
  • cyclodextrin
  • cyclohexaamylose
  • cyclomaltohexaose

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT07079761Phase 2Aug 4, 2025Harvard University, National Institute of Mental Health (NIMH)
NCT06489340Phase 2Jul 31, 2024ZyVersa Therapeutics, Inc.
NCT05261386Phase 2Mar 24, 2022ADS AIPHIA Development Services AG, Cloudbreak Therapeutics, LLC
NCT04932265Phase 1Sep 30, 2021EuroPharma, Inc., Government of Armenia, Institute of Fine Organic Chemistry of the National Academy of Science, Armenia, Institute of Fine Organic Chemistry of the National Academy of Science Yerevan, Armenia, Phytomed AB
NCT04130802Phase 2Sep 27, 2019Oculis
NCT03931057Phase 2Jun 30, 2019Medical University of Vienna
NCT05393843Phase 4May 1, 2018A.O. Ospedale Maggiore di Lodi
NCT03002168N/AJan 1, 2017Mayo Clinic, SFI Research
NCT02999620N/AJan 1, 2017Mayo Clinic, SFI Research
NCT01960621Phase 4Aug 1, 2016University of London
NCT02055716Phase 1Jan 1, 2014Evgen Pharma, Richmond Pharmacology
NCT01948362Phase 1Nov 1, 2012Evgen Pharma, Richmond Pharmacology
NCT01131299Phase 2Mar 1, 2010National Heart, Lung, and Blood Institute (NHLBI), National Institutes of Health (NIH)
NCT03624842N/A—Cyclotherapeutics, Kerwin Research Center
Showing 14 of 14 trials
Page 1 / 1

Organizations

Research & Development (22)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
Evgen PharmaFor profit2212012
Mayo ClinicAcademic/Hospital2112017
Richmond PharmacologyFor profit2012012
SFI ResearchAcademic/Hospital2112017
ADS AIPHIA Development Services AGFor profit1012022
A.O. Ospedale Maggiore di LodiAcademic/Hospital1112018
Cloudbreak Therapeutics, LLCFor profit1112022
CyclotherapeuticsFor profit111—
EuroPharma, Inc.For profit1112021
Government of ArmeniaGovernment1012021
Harvard UniversityAcademic/Hospital1112025
Institute of Fine Organic Chemistry of the National Academy of Science, ArmeniaAcademic/Hospital1012021
Institute of Fine Organic Chemistry of the National Academy of Science Yerevan, ArmeniaAcademic/Hospital1012021
Kerwin Research CenterAcademic/Hospital101—
Medical University of ViennaAcademic/Hospital1112019
National Heart, Lung, and Blood Institute (NHLBI)Government1112010
National Institute of Mental Health (NIMH)Government1012025
National Institutes of Health (NIH)Government1012010
OculisFor profit1112019
Phytomed ABFor profit1012021
22 organizations
Page 1 / 2